**Name of Journal:** *World Journal of Gastrointestinal Endoscopy*

**Manuscript NO:** 48831

**Manuscript Type:** LETTER TO THE EDITOR

**Has the time been reached for pseudopolyps to be re-enrolled in endoscopic inflammatory bowel disease scores?**

Politis DS *et al*. Pseudopolyps for IBD scores

Dimitrios S Politis, Konstantinos H Katsanos, Konstantinos Papamichael, Maria Saridi, Eleni Albani, Dimitrios K Christodoulou

**Dimitrios S Politis, Konstantinos H Katsanos, Dimitrios K Christodoulou,** Department of Gastroenterology, University Hospital of Ioannina, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina 45110, Greece

**Konstantinos Papamichael,** Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, United States

**Maria Saridi,** General Hospital of Corinth, Department of Social and Educational Policy, University of Peloponnese, Corinth 20100, Greece

**Eleni Albani,** Department of Nursing, TEI of Western Greece, Patra 26334, Greece

**ORCID number:** Dimitrios S Politis (0000-0002-2294-4972); Konstantinos H Katsanos (0000-0002-3273-0417); Konstantinos Papamichael (0000-0003-1497-0254); Maria Saridi (0000-0002-9008-824X); Eleni Albani (0000-0001-7340-4696); Dimitrios K Christodoulou (0000-0001-9694-1160).

**Author contributions:** All authors contributed to the conception, literature review, drafting and revising of the manuscript, and provided approval of the final form.

**Conflict-of-interest statement:** All authors declare no conflicts of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Corresponding author:** **Dimitrios S Politis, FEBG, MD, PhD, Doctor,** Department of Gastroenterology, University Hospital of Ioannina, Faculty of Medicine, School of Health Sciences, University of Ioannina, Leoforos Stavrou Niarchou, Ioannina 45110, Greece. [politisdimitrios1@gmail.com](mailto:politisdimitrios1@gmail.com)

**Telephone:** + 30-26-51099867

**Fax:** + 30-26-51007016

**Received:** May 5, 2019

**Peer-review started:** May 8, 2019

**First decision:** May 31, 2019

**Revised:** June 5, 2019

**Accepted:** June 10, 2019

**Article in press:**

**Published online:**

**Abstract**

Patients with inflammatory bowel diseases (IBD) represent heterogeneous groups with different characteristics and different clinical course. A great deal of effort is made to discover proxies for more severe disease needing more intense treatment and early intervention to gain the maximum therapeutic benefit. Endoscopy remains an invaluable method in assessment of patients with IBD. Pseudopolyps are often encountered during endoscopy and, although they are a well described entity, their presence is of unclear importance. In one of our recent studies and in conjunction with one study with a large cohort of patients with IBD and pseudopolyps, patients with pseudopolyps were found to face a higher inflammatory burden in terms of receiving more intense biological treatment. This letter comes as a comment and proposition regarding the concept of re-evaluation of pseudopolyps as a promising marker in IBD scores.

**Key words:** Pseudopolyps; Inflammatory bowel diseases; Treatment escalation; Endoscopic scores

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Interest in pseudopolyps and their relationship for monitoring inflammatory bowel disease activity has been refreshed by two recent studies that showed the presence of pseudopolyps to be linked with escalation of treatment, including the increased need for use of biological agents. The next logical step in their management is including their evaluation and possible integration, after proper validation, in inflammatory bowel disease scores, as separate markers for prediction of a more severe clinical course.

Politis DS, Katsanos KH, Papamichael K, Saridi M, Albani E, Christodoulou DK. Has the time been reached for pseudopolyps to be re-enrolled in endoscopic inflammatory bowel disease scores? *World J Gastrointest Endosc* 2019; In press

**TO THE EDITOR**

The modern mentality of the management of inflammatory bowel diseases (IBDs) is imposed by the concept of the window of opportunity for medical intervention, alongside accurate understanding of and reduction in the inflammatory burden for each patient early in the clinical course[1,2]; the high economic impact of the use of biological agents should also be taken into account[3]. This aspect creates increased needs for recognition of subgroups of IBD patients who benefit from the newer treatments, through the use of validated markers and risk factors. Even though pseudopolyps or post-inflammatory polyps (PIPs) are a well described entity in the literature, their utility as a predictive marker in IBD remains ambitious. Although PIPs were evaluated as a candidate variable in the development of the Crohn's Disease Endoscopic Index of Severity (referred to as CDEIS), they were not integrated into the final score as they did not seem to alter the endoscopist's global evaluation of colitis severity[4].

In a recent publication by Mahmoud *et al*[5], the authors presented one of the largest populations of patients with PIPs in the literature: 462 patients. In addition to the primary outcome showing negative association of PIPs with colorectal neoplasia in IBD patients, results of great significance were the association of PIPs with higher colectomy rate (*P* = 0.01) and the association of the presence of PIPs with more severe inflammation occurring in the era of biological treatments [adjusted odds ratio = 1.32; 95% confidence interval (CI): 1.13-1.55]. Another interesting finding of the study, even though mentioned mainly in the tables, is that patients with PIPs received biological agents at a higher rate in comparison with the non-PIPs patients (27.1% *vs* 17.5% respectively, *P* < 0.0005).

We have recently presented a retrospective study of a small series of 83 patients with ulcerative colitis, including 25 (30%) with PIPs. We found that the presence of PIPs was associated with higher need for treatment escalation [hazard ratio (HR) = 2.3; 95%CI: 1.2-4.3, *P* = 0.014][6]. In addition, our analysis also showed a higher need for biological treatment and colectomy in the group of patients with PIPs (HR = 6.3; 95%CI: 1.9-20.7, *P* = 0.002) and that the need for treatment escalation occurred early (during the first 2 years in the clinical course) for the majority of the patients. Our sample size was small but well studied with tight inclusion criteria regarding the endoscopic data and the clinical follow-up.

From a new perspective, these data collectively support the concept that PIPs are linked with more severe inflammatory burden, as implied by the higher need for more intense immunosuppression. It is our belief that there are sufficient data to restart the discussion about the incorporation of PIPs into endoscopic IBD scores as a distinctive marker. Their utility as a marker is advocated by their relatively simple identification during endoscopy, presenting early in the clinical course and being present both in flares and remission of the IBD. Α distinct parameter of importance for evaluation could be, not just the criteria of their presence but also their histological findings, since the clinical and histological activities are not always parallel in the IBD course[7].

Overall, PIPs are a common and interesting finding in IBD patients and may have an additional role in helping us recognize a subpopulation of IBD patients with high inflammatory burden who may benefit from earlier therapeutic intervention.

**REFERENCES**

1 **Lega S**, Dubinsky MC. What Are the Targets of Inflammatory Bowel Disease Management. *Inflamm Bowel Dis* 2018; **24**: 1670-1675 [PMID: 29697788 DOI: 10.1093/ibd/izy064]

2 **Peyrin-Biroulet L**, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV Jr, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. *Am J Gastroenterol* 2015; **110**: 1324-1338 [PMID: 26303131 DOI: 10.1038/ajg.2015.233]

3 **Pillai N**, Dusheiko M, Burnand B, Pittet V. A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. *PLoS One* 2017; **12**: e0185500 [PMID: 28973005 DOI: 10.1371/journal.pone.0185500]

4 **Mary JY**, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). *Gut* 1989; **30**: 983-989 [PMID: 2668130 DOI: 10.1136/gut.30.7.983]

5 **Mahmoud R**, Shah SC, Ten Hove JR, Torres J, Mooiweer E, Castaneda D, Glass J, Elman J, Kumar A, Axelrad J, Ullman T, Colombel JF, Oldenburg B, Itzkowitz SH; Dutch Initiative on Crohn and Colitis. No Association Between Pseudopolyps and Colorectal Neoplasia in Patients With Inflammatory Bowel Diseases. *Gastroenterology* 2019; **156**: 1333-1344.e3 [PMID: 30529584 DOI: 10.1053/j.gastro.2018.11.067]

6 **Politis DS**, Papamichael K, Katsanos KH, Koulouridis I, Mavromati D, Tsianos EV, Christodoulou DK. Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation. *Ann Gastroenterol* 2019; **32**: 168-173 [PMID: 30837789 DOI: 10.20524/aog.2019.0357]

7 **Politis DS**, Katsanos KH, Tsianos EV, Christodoulou DK. Pseudopolyps in inflammatory bowel diseases: Have we learned enough? *World J Gastroenterol* 2017; **23**: 1541-1551 [PMID: 28321155 DOI: 10.3748/wjg.v23.i9.1541]

**P-Reviewer:**  Sipos F **S-Editor:** Dou Y **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Greece

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0